In a landmark decision that could reshape how medtech companies approach intellectual property litigation, a U.S. appeals court has overturned a $59.4 million trade secret misappropriation award against South Korean medical device manufacturer EOFlow. The ruling marks a significant victory for the Seoul-based firm and underscores the critical importance of statutes of limitations in high-stakes intellectual property disputes.
The appellate court’s decision hinges on a fundamental principle of trade secret law: the "discovery rule." The court determined that Insulet—the maker of the ubiquitous Omnipod insulin management system—failed to initiate legal action within the legally mandated window, despite having clear indicators that its intellectual property might have been compromised years earlier.
The Core Facts of the Dispute
At the heart of the legal battle was the EOPatch, an insulin pump developed by EOFlow, which Insulet claimed was built upon misappropriated trade secrets related to its own Omnipod technology.
In August 2023, Insulet filed a formal complaint alleging that EOFlow had improperly acquired proprietary information. The legal conflict moved rapidly through the court system, culminating in a December 2024 jury verdict that initially found EOFlow guilty of misappropriation and awarded Insulet a staggering $452 million in damages. Following a series of post-trial motions—where EOFlow argued that the requested permanent injunction was duplicative of the damages—a court reduced the award to $59.4 million.
However, the recent appellate ruling has effectively erased that judgment entirely. The court found that the evidence of Insulet’s awareness of potential infringement dated back to as early as 2018, far exceeding the three-year statute of limitations required under U.S. law for trade secret misappropriation claims.
Chronology: A Trail of Evidence
The appellate court’s decision was heavily influenced by a timeline of events that, according to the judges, demonstrated that Insulet possessed enough information to act long before it filed its 2023 lawsuit.
- 2018: During a medical technology conference, Insulet personnel were observed photographing EOFlow device samples. In the days following this interaction, logs indicated that Insulet representatives visited the EOFlow website approximately 20 times.
- 2019: Jonathan Paris, Insulet’s deputy general counsel, reportedly conducted an in-person examination of the EOFlow booth at an industry trade event, further deepening the company’s familiarity with their competitor’s technology.
- May 2023: Medtronic announced an agreement to acquire EOFlow for approximately $738 million, a move that would have positioned the South Korean firm as a major player in the global diabetes management market.
- August 3, 2023: Insulet officially filed its complaint against EOFlow, alleging trade secret theft.
- December 2023: Citing "multiple breaches" of their acquisition agreements, Medtronic formally canceled its plan to acquire EOFlow, a decision heavily influenced by the legal cloud cast by the ongoing Insulet litigation.
- December 2024: A federal jury delivered a massive $452 million verdict in favor of Insulet.
- 2025 (Appellate Ruling): The appeals court overturns the $59.4 million judgment, ruling that Insulet’s delay in filing the suit rendered the claims invalid.
Analyzing the Court’s Reasoning
The appellate panel’s majority opinion rested on the "knew or should have known" standard. By law, companies have three years from the moment they discover—or should have reasonably discovered—the misappropriation of trade secrets to file a lawsuit.
Two of the three judges presiding over the appeal concluded that the 2018 conference photographs and the subsequent surge in website traffic to EOFlow’s portal provided "undisputed evidence" that Insulet was aware of the similarities between its own proprietary technology and the EOPatch 2. By failing to initiate legal action within the three-year window following these events, the court ruled that Insulet had forfeited its right to pursue these specific claims.
The Dissenting Perspective
Not all members of the court agreed with the majority’s assessment. One judge filed a dissenting opinion, arguing that the court had overstepped its role by second-guessing the jury. The dissenter posited that it was the jury’s responsibility to determine whether Insulet’s early investigative efforts—the booth visits and web searches—constituted actual knowledge of misappropriation or were merely standard industry research. By overturning the verdict, the majority effectively stripped the jury of its role as the finder of fact.
Official Responses and Legal Perspectives
The legal team representing EOFlow, led by Cooley partner Elizabeth Prelogar, viewed the decision as a vindication of both their client and the broader principle of innovation. In an emailed statement following the ruling, Prelogar emphasized that the court’s decision sends a strong signal to the industry: parties alleging trade secret violations must exercise due diligence and act with promptness.
"This decision is a sweeping victory for EOFlow and for innovation," Prelogar stated. By requiring companies to act within a strict timeframe, the court has ensured that potential plaintiffs cannot "sit on their hands" while a competitor grows, only to sue once that competitor becomes a lucrative acquisition target.
Insulet, meanwhile, has yet to issue a comprehensive response regarding its next steps, though the ruling represents a significant blow to the company’s efforts to protect its market share in the competitive insulin pump space.
Implications for the Medtech Industry
The fallout from this case is likely to be felt throughout the medical device sector for years to come.
1. The Weaponization of Litigation
The case highlights the thin line between legitimate competitive intelligence and actionable trade secret theft. In an industry where technological advancements are incremental and highly guarded, companies frequently monitor their rivals. This ruling warns that such monitoring must be documented carefully, as it can be used against the company to trigger the start of the statute of limitations.
2. The Impact on M&A Activity
The collapse of the Medtronic-EOFlow deal serves as a cautionary tale for the M&A landscape. When a target company becomes the subject of a high-profile lawsuit, it creates immense uncertainty. Even if the target company is later vindicated, the legal costs, reputation damage, and delayed timelines can be fatal to an acquisition. This case may encourage prospective buyers to perform even deeper "IP audits" before signing acquisition agreements.
3. Strengthening the "Discovery Rule"
By strictly enforcing the statute of limitations, the appeals court has reinforced a pro-competition stance. The ruling prevents established market leaders from using the threat of long-term litigation to stifle emerging competitors. It forces companies to prioritize legal action early in the product lifecycle rather than waiting until a competitor has achieved a level of commercial success that makes a lawsuit more financially rewarding.
4. A Call for Diligence
For general counsel and IP departments, the takeaway is clear: if there is a suspected infringement, the clock starts ticking immediately. Companies must weigh the risks of early litigation against the risk of losing their legal standing entirely. The "wait and see" approach, while sometimes prudent for business strategy, has proven to be a dangerous legal gamble.
Conclusion
The reversal of the $59.4 million award in the Insulet v. EOFlow case is more than just a legal technicality; it is a critical reminder of the temporal boundaries of intellectual property protection. As the medtech industry continues to innovate at a rapid pace, the legal frameworks governing that innovation—and the timing of their enforcement—will remain a primary concern for companies, investors, and legal practitioners alike. EOFlow, having survived both a hostile legal battle and a failed acquisition, now stands as a testament to the power of a robust defense against stale claims.
